Sagimet Biosciences Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Happel
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 155 Bovet Road San Mateo CA United States of America 94402
- IPO Date
- Jul 14, 2023
- CIK
- 0001400118
- Website
- sagimet.com
- Similar Companies
- Business
- Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel fatty acid synthase (FASN) inhibitors aimed at treating dysfunctional metabolic and fibrotic pathways in diseases caused by overproduction of the fatty acid palmitate. The company's primary products include its lead drug candidate denifanstat, an oral, once-daily selective FASN inhibitor in clinical development for metabolic dysfunction associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Denifanstat is also being evaluated in Phase 2 trials for moderate to severe acne vulgaris and in Phase 3 trials for recurrent glioblastoma multiforme in partnership with Ascletis Bioscience Co. Ltd. Additionally, Sagimet is developing TVB-3567, a second FASN inhibitor in early clinical trials for acne. The company operates mainly in the United States and China through collaborative partnerships and clinical trial sites. Founded in 2006, Sagimet Biosciences is headquartered in San Mateo, California. Recently, Sagimet has advanced its pipeline with a Phase 1 pharmacokinetic trial combining denifanstat and resmetirom in healthy adults, with topline data expected in the first half of 2026 to support further development in MASH patients with advanced liver fibrosis (F4). The license partner Ascletis has completed a pre-NDA consultation in China for denifanstat in moderate-to-severe acne following a successful Phase 3 trial that met all efficacy endpoints, supporting an upcoming NDA submission. Sagimet also commenced a first-in-human Phase 1 trial for TVB-3567 targeting acne, expanding its clinical portfolio. Financially, as of the third quarter of 2025, the company reported a net loss of $41.5 million over nine months with cash and marketable securities totaling approximately $125.5 million, enabling continued clinical development and strategic initiatives. These developments mark significant progress in Sagimet's expansion into multiple disease areas driven by fatty acid metabolism dysregulation.
Company News
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of “Moderate Buy” from Analysts
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
Why Is Sagimet Biosciences Stock Trading Higher On Monday?